Coherus Oncology, Inc. (CHRS)

Coherus Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	168.02	28.51	-237.89	-291.75	-287.1
Depreciation & Amortization	3.92	5.28	3.79	3.7	3.45
Stock-Based Compensation	16.97	27.8	43.11	50.74	51.36
Other Adjustments	-321.59	-137.92	52.93	75.45	152.49
Change in Receivables	93.56	149.35	-150.66	13.05	34.06
Changes in Inventories	-17.11	-31.95	-46.72	-47.25	-6.25
Changes in Accounts Payable	-19.56	-3.94	23.76	-4.54	0.87
Changes in Accrued Expenses	-123.09	-4.52	107.63	-23.67	-2.73
Changes in Other Operating Activities	60.36	-53.05	34.1	-16.44	16.41
Operating Cash Flow	-138.51	-20.44	-174.88	-241.12	-37.43
Capital Expenditures	-	-	-	-	-1.29
Purchases of Investments	-103.84	-	-19.51	-127.38	-182.49
Proceeds from Sale of Investments	21.46	14.89	157.64	-	181.36
Other Investing Activities	457.46	215.43	6.51	-39.47	-136
Investing Cash Flow	375.09	230.32	144.64	-166.85	-138.41
Long-Term Debt Issued	-47.65	73.47	-	240.68	-
Long-Term Debt Repaid	-233.19	-260.39	-	-190.75	-
Net Long-Term Debt Issued (Repaid)	-280.84	-186.92	-	49.93	-
Issuance of Common Stock	8.25	2.38	74.22	9.37	54.3
Repurchase of Common Stock	-0.28	-2.48	-3.59	-3.74	-1.75
Net Common Stock Issued (Repurchased)	7.96	-0.1	70.63	5.63	52.55
Other Financing Activities	-0.83	0.04	-1.03	-1.23	-0.67
Financing Cash Flow	-273.71	-186.97	69.6	54.33	51.88
Net Cash Flow	-37.13	22.91	39.36	-353.65	-123.96
Free Cash Flow	-138.51	-20.44	-174.88	-241.12	-38.72
FCF Margin	-328.45%	-77.46%	-67.98%	-114.25%	-11.86%
Free Cash Flow Per Share	-1.18	-0.18	-1.86	-3.11	-0.51
Levered Free Cash Flow	142.86	-2.69	-115.33	-330.03	-276.64
Unlevered Free Cash Flow	-276.61	-287.83	-80.32	-345.08	-253.4

Updated Mar 9, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q